David E. Avigan
Experienced in Mondor Disease

Dr. David E. Avigan

Internal Medicine | Oncology
330 Brookline Avenue, Shapiro 7, 
Boston, MA 
On Staff At
33 Years of Experience
Experienced in Mondor Disease
330 Brookline Avenue, Shapiro 7, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Avigan is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Avigan has been practicing medicine for over 33 years and is rated as an Experienced provider by MediFind in the treatment of Mondor Disease. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Yale University School Of Medicine
Residency
Columbia Presbyterian Medical Center
Specialties
Internal Medicine
Oncology
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
Memorial Sloan- Kettering Cancer Center
Hospital Affiliations
Beth Israel Deaconess Hospital - Needham
Beth Israel Deaconess Medical Center
Languages Spoken
English
Hebrew
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 7, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: GO-203-2C, Decitabine
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Enrollment Status: Completed
Publish Date: April 03, 2023
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 27, 2023
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1
A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients
A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients
Enrollment Status: Unknown
Publish Date: September 08, 2022
Intervention Type: Biological
Study Drug: TEG002
Study Phase: Phase 1
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 18, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: Busulfan, Fludarabine, Tacrolimus, Methotrexate, GM-CSF-Positive GVAX Vaccine
Study Phase: Phase 2
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation
Enrollment Status: Completed
Publish Date: January 23, 2019
Intervention Type: Biological, Radiation, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

121 Total Publications

Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
Journal: Blood cancer discovery
Published: June 05, 2025
Similar Doctors
Kenneth A. Bauer
Experienced in Mondor Disease
Dr. Kenneth A. Bauer
Internal Medicine | Oncology
Experienced in Mondor Disease
Dr. Kenneth A. Bauer
Internal Medicine | Oncology

Beth Israel Deaconess Medical Center

330 Brookline Avenue, E/tcc-9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kenneth Bauer is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Bauer is rated as a Distinguished provider by MediFind in the treatment of Mondor Disease. His top areas of expertise are Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism (VTE), Embolectomy, and Thrombectomy.

Experienced in Mondor Disease
Dr. Jonathan B. Croopnick
Hematology Oncology | Hematology | Oncology
Experienced in Mondor Disease
Dr. Jonathan B. Croopnick
Hematology Oncology | Hematology | Oncology

Lifespan Physician Group Of Massachusetts Inc

70 Walnut St, Suite 100, 
Foxborough, MA 
 (21.1 miles away)
508-698-3266
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Croopnick is a Hematologist Oncology specialist and a Hematologist in Foxborough, Massachusetts. Dr. Croopnick is rated as an Advanced provider by MediFind in the treatment of Mondor Disease. His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Croopnick is currently accepting new patients.

Experienced in Mondor Disease
Dr. Rebecca S. Karp
Hematology Oncology | Hematology | Oncology
Experienced in Mondor Disease
Dr. Rebecca S. Karp
Hematology Oncology | Hematology | Oncology

The General Hospital Corporation

40 2nd Ave, 
Waltham, MA 
 (9.0 miles away)
781-487-2900
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rebecca Karp is a Hematologist Oncology specialist and a Hematologist in Waltham, Massachusetts. Dr. Karp has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Mondor Disease. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Childhood Iron Deficiency Anemia, Shwartzman Phenomenon, and Protoporphyria. Dr. Karp is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Avigan's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 24 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile